382 related articles for article (PubMed ID: 8267397)
21. CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases.
Piantino P; Andriulli A; Gindro T; Pecchio F; Masoero G; Cavallini G; Naccarato R; Dobrilla G
Am J Gastroenterol; 1986 Jun; 81(6):436-9. PubMed ID: 3458359
[TBL] [Abstract][Full Text] [Related]
22. Tissue polypeptide antigen, galactosyltransferase isoenzyme II and pancreatic oncofetal antigen serum determination: role in pancreatic cancer diagnosis.
Basso D; Fabris C; Panucci A; Del Favero G; Angonese C; Plebani M; Petrin P; Burlina A; Naccarato R
Int J Pancreatol; 1988; 3 Suppl 1():S95-100. PubMed ID: 3145303
[TBL] [Abstract][Full Text] [Related]
23. Tumour markers in pancreatic cancer.
Haglund C; Kuusela P; Roberts PJ
Ann Chir Gynaecol; 1989; 78(1):41-53. PubMed ID: 2667448
[TBL] [Abstract][Full Text] [Related]
24. [Tumor markers for pancreatic and biliary tract cancer].
Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
[TBL] [Abstract][Full Text] [Related]
25. [Tumor markers in the upper intestinal tract--stomach and pancreas].
Pointner R; Conrad F; Schwab G
Wien Klin Wochenschr; 1989 Jul; 101(14):482-4. PubMed ID: 2773485
[TBL] [Abstract][Full Text] [Related]
26. The prognostic value of the tumour markers CA 195 and CEA in patients with adenocarcinoma of the pancreas.
Taylor OM; Cooper EH; Benson EA; McMahon MJ
Eur J Surg Oncol; 1992 Oct; 18(5):508-13. PubMed ID: 1426303
[TBL] [Abstract][Full Text] [Related]
27. Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
J Cancer Res Clin Oncol; 1994; 120(8):494-7. PubMed ID: 8207049
[TBL] [Abstract][Full Text] [Related]
28. Gallbladder bile tumor marker quantification for detection of pancreato-biliary malignancies.
Brockmann J; Emparan C; Hernandez CA; Sulkowski U; Dietl KH; Menzel J; Wolters H; Glodny B; Senninger N
Anticancer Res; 2000; 20(6D):4941-7. PubMed ID: 11326643
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
30. The clinical relevance of the tumor marker CA 19-9 in the diagnosing and monitoring of pancreatic carcinoma.
Safi F; Roscher R; Beger HG
Bull Cancer; 1990; 77(1):83-91. PubMed ID: 2180502
[TBL] [Abstract][Full Text] [Related]
31. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
[TBL] [Abstract][Full Text] [Related]
32. [Clinical evaluation of CA 19-9, TPA, IAP and 5'-NPD-V as tumor markers of hepatocellular, bile duct and pancreas carcinoma].
Takahashi H; Miyazaki H; Deura M; Shimizu Y; Asukata I; Kameda H
Gan No Rinsho; 1985 May; 31(6 Suppl):623-30. PubMed ID: 2411964
[TBL] [Abstract][Full Text] [Related]
33. [New prospects in the combined use of tumor markers in epithelial neoplasms of the ovary].
Indraccolo SR; Cecchi A; Thodos A; Brandi S; Carta G
Ann Ostet Ginecol Med Perinat; 1991; 112(1):36-40. PubMed ID: 1929097
[TBL] [Abstract][Full Text] [Related]
34. [Value of CA 125 in comparison to conventional tumor markers in ovarian cancer].
Paulick R; Kaesemann H; Caffier H
Geburtshilfe Frauenheilkd; 1986 Aug; 46(8):509-14. PubMed ID: 2875919
[TBL] [Abstract][Full Text] [Related]
35. [Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases].
Czakó L; Takács T; Babarczy E; Dux L; Lonovics J
Orv Hetil; 1997 Nov; 138(47):2981-5. PubMed ID: 9432648
[TBL] [Abstract][Full Text] [Related]
36. [The L.A.I. test and tumor markers (Ca 19-9 and TPA) in the diagnosis of pancreatic carcinoma].
Meduri F; Bizzarini M; Diana F; Merenda R; Gerunda GE; Doni MG; Maffei Faccioli A
Minerva Chir; 1989 Aug; 44(15-16):1777-81. PubMed ID: 2682370
[TBL] [Abstract][Full Text] [Related]
37. Different role of liver dysfunction and damage in increasing serum CA 19-9, TPA, and CEA in patients with pancreatic cancer.
Fabris C; Basso D; Meggiato T; Del Favero G; Piccoli A; Fogar P; Panozzo MP; Faggian D; Naccarato R
Int J Pancreatol; 1990 Jan; 6(1):i-ii. PubMed ID: 2230355
[No Abstract] [Full Text] [Related]
38. The tumor markers CEA, TPA and CA 19-9 in gastric cancer.
Putzki H; Reichert B; Jablonski M; Heymann H
Dtsch Z Verdau Stoffwechselkr; 1988; 48(3-4):145-8. PubMed ID: 3234297
[TBL] [Abstract][Full Text] [Related]
39. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
[TBL] [Abstract][Full Text] [Related]
40. [Role of carcinoembryonic antigen, carbohydrate antigen 19-9 and cytology of bile in diagnosis of biliary and pancreatic cancer].
Matsuda M; Shimizu Y; Chikamatsu E; Takayanagi K; Ishigure H; Murakami S; Odani K
Nihon Geka Gakkai Zasshi; 1991 Jun; 92(6):716-21. PubMed ID: 1886576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]